Sex and Gender
Science or Snake Oil: Will the NHS Puberty Blocker Trial Harm More Than It Helps?
In spring 2025, NHS England may launch its much-anticipated “Pathways” trial into puberty blockers, a £10.7 million endeavour led by King’s College London and backed by the National Institute for Health and Care Research. This follows the Cass Review’s damning verdict on the thin evidence behind these drugs—gonadotropin-releasing hormone agonists used to pause puberty in children with gender dysphoria—and a subsequent halt to their routine use in March 2024. With recruitment set to begin via England’s new regional gender services, the study promises answers where Cass found none. Yet, as The Quackometer has long cautioned, clinical trials can be fertile [read more...]
